Popular keto diet set to be tested in humans to see if it can amp up effect of weak PI3K drugs
Could a popular diet be put on the menu of treatment options for some cancer patients? A new mouse study suggests that the answer might be yes — and a marquee scientist in the field is set to test it in humans.
Combining a ketogenic diet with PI3K inhibitors like Zydelig (Gilead) and Aliqopa (from Bayer) appears to be an effective way to combat the interference of an insulin response mechanism triggered when the drug interrupts insulin production and then sets off an alternative spike in insulin production which may well be responsible for either reducing or eliminating its efficacy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.